New Delhi: Bharat Biotech’s corona-fighting intranasal vaccine has received approval from the Central Drugs Standard Control Organization (CDSCO) for a heterologous booster for restricted use in emergencies in India for people 18 years and above. Heterologous booster means that any person who has taken covidshield or covaccine dose can also be given this special intranasal vaccine as a booster dose.
Bharat Biotech Company has said in its statement that the Phase III clinical trial of this particular vaccine was also done, which was successful. The company has told that the people involved in the first and second phase trials were also evaluated. Krishna Ella, chairman and managing director of Bharat Biotech, had recently said that the firm had completed clinical trials of the nasal vaccine on around 4,000 volunteers and not a single case of side effect has been reported so far.
Nasal vaccine can be used as primary second dose
Apart from this, he said that the nasal vaccine can be used as primary second dose and heterologous booster dose. This is a big achievement for the scientific community around the world and those who prepare the Covid vaccine. Apart from this, he said that even though the demand for Covid vaccine has decreased, but still we are continuously making internal vaccine so that we can be prepared for future diseases.
Last Friday, DCGI gave approval for emergency use
Let us tell you that recently the booster dose of Covid-19 Nasal Vaccine was approved by the Emergency Use Authority from the Drugs Controller of India on last Friday. Bharat Biotech claimed that the intranasal vaccine provokes a broad immune response and has the potential to block both infection and transmission of COVID-19. On 6 September, the DCGI approved its intranasal Covid vaccine iNCOVACC for restricted emergency use in those above 18 years of age.
